Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YKYY025 in Healthy Adult Participants
NCT07694557Phase 1Recruiting
- Sponsor
- Yuekang Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing YKYY025 group with YKYY025 Placebo group (2 arms). Primary endpoints: Adverse Events at 30 days, Serious Adverse Events at 12 months and 4 more. Started Jul 2026; status: recruiting.
02
Drugs
YKYY025
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07694557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07694557.